View More View Less
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    https://www.cdc.gov/flu/pandemic-resources/1918-pandemic-h1n1.html

  • 2

    Wang X, Li Y, O’Brien KL, et al. Respiratory Virus Global Epidemiology Network. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Global Health 2020; 8: e497–e510.

  • 3

    https://www.cdc.gov/flu/about/burden/2018-2019.html

  • 4

    Tyrrell CSB, Allen JL, Carson G. Influenza and other emerging respiratory viruses. Medicine (Abingdon) 2017; 45: 781–787.

  • 5

    https://theconversation.com/the-mysterious-disappearance-of-the-first-sars-virus-and-why-we-need-a-vaccine-for-the-current-one-but-didnt-for-the-other-137583

  • 6

    https://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.df?ua=1&ua=1&ua=1&ua=1&ua=1&ua=1

  • 7

    https://www.worldometers.info/coronavirus/

  • 8

    https://www.worldometers.info/coronavirus/country/hungary/

  • 9

    https://home.kpmg/xx/en/home/insights/2020/04/ukraine-government-and-institution-measures-in-response-to-covid.html

  • 10

    https://www.rki.de/EN/Home/homepage.html

  • 11

    Meenakshisundaram R, Senthilkumaran S, Thirumalaikolundusubramanian P. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis. Med Hypotheses 2020; 26: 143: 109849.

  • 12

    https://www.researchgate.net/publication/341354165_MMR_Vaccine_Appears_to_Confer_Strong_Protection_from_COVID-19_Few_Deaths_from_SARS-CoV-2_in_Highly_Vaccinated_Populations?channel=doi&linkId=5ebc0220a6fdcc90d67350c9&showFulltext=true

  • 13

    Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Update Alert: Should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living practice points from the American College of Physicians. Ann Intern Med. 2020 Jun 17. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 14

    Fábián Á, László I, Juhász M, et al. Pharmacological options in treating SASR-CoV-2 infection/COVID-19. [Farmakoterápiás lehetőségek SARS-CoV-2-fertőzés/COVID–19-betegség esetén.] Orv Hetil. 2020; 161: 685–688. [Hungarian]

  • 15

    Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med. 2020 May 22. . [Published online ahead of print]

    • Crossref
    • Export Citation
  • 16

    Bobek I, Gopcsa L, Réti M. et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. [Az első két sikeres, convalescens friss fagyasztott plazmával történő terápia hazai alkalmazása intenzív osztályon kezelt, kritikus állapotú, COVID–19-fertőzésben szenvedő betegekben.] Orv Hetil. 2020; 161: 1111–1121. [Hungarian]

  • 17

    Lakatos B, Gopcsa L, Gondos E, et al. Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology. [Citokinellenes terápia az új típusú koronavírus okozta megbetegedés (COVID–19) kezelésében – tocilizumab elsőként való alkalmazása egy hazai infektológiai osztályon.] Orv Hetil. 2020; 161: 1070–1077. [Hungarian]

  • 18

    Gál J, Fülesdi B. The intesive care requires conceptional changes in Hungary. [Koncepcionális átalakulásra szorul a hazai intenzív ellátás.] Orv Hetil. 2011; 152: 94 [Hungarian]